Compare UPST & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UPST | SUPN |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2020 | 2010 |
| Metric | UPST | SUPN |
|---|---|---|
| Price | $26.82 | $46.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $45.84 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 3.6M | 854.3K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,043,857,000.00 | $392,755,000.00 |
| Revenue This Year | $34.45 | $22.70 |
| Revenue Next Year | $32.64 | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 63.99 | N/A |
| 52 Week Low | $23.97 | $32.83 |
| 52 Week High | $85.31 | $59.68 |
| Indicator | UPST | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 45.67 |
| Support Level | $25.18 | $43.43 |
| Resistance Level | $34.84 | $46.79 |
| Average True Range (ATR) | 1.62 | 1.65 |
| MACD | -0.65 | -0.16 |
| Stochastic Oscillator | 1.37 | 4.62 |
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.